Venetoclax rituximab is superior to Bendamustin rituximab in progression-free survival in patients with recurrent or refractory CLL. A Phase III study was published in the New England Journal of Medicine (NEJM) on March 22, 2018 in which a total of n = 389 patients with recurrent...

Start of the series "Oncological care in everyday life" with a report on the development of anti-emetic strategies for platinum-containing therapies in oncological practices, from 2012-2017 At the end of 2017, GermanOncology and the German Oncology Foundation (www.stiftung-deutsche-onkologie.de) started a series of reports that will provide insights...

Amended guideline for outpatient specialist medical care (ASV) for gastrointestinal tumours and tumours of the abdominal cavity approved by the Federal Ministry of Health On July 4, 2016, it was published on the website of the Federal Joint Committee (G-BA) that the Federal Ministry of Health...